Aardvark Therapeutics (NASDAQ:AARD) Insider Nelson Sun Sells 62,000 Shares

Aardvark Therapeutics, Inc. (NASDAQ:AARD) insider Nelson Sun sold 62,000 shares of the company’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $5.18, for a total transaction of $321,160.00. Following the completion of the transaction, the insider owned 35,475 shares of the company’s stock, valued at $183,760.50. This represents a 63.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Nelson Sun also recently made the following trade(s):

• On Thursday, September 10th, Nelson Sun sold 14,754 shares of Aardvark Therapeutics stock. The shares were sold at an average price of $5.00, for a total value of $73,770.00.

Aardvark Therapeutics Stock Up 2.4%

NASDAQ:AARD traded up $0.12 during mid-day trading on Friday, reaching $5.13. 276,559 shares of the stock were exchanged, compared to its average volume of 128,424. The stock has a market capitalization of $112.24 million, a P/E ratio of -1.60 and a beta of 3.74. Aardvark Therapeutics, Inc. has a 1 year low of $3.35 and a 1 year high of $17.94. The company has a 50 day simple moving average of $6.29 and a 200-day simple moving average of $5.53.

Aardvark Therapeutics (NASDAQ:AARD) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.21. As a group, research analysts predict that Aardvark Therapeutics, Inc. will post -3.17 EPS for the current year.

Key Stories Impacting Aardvark Therapeutics

Here are the key news stories impacting Aardvark Therapeutics this week:

• Positive Sentiment: No company-specific clinical, regulatory, or financial improvement was reported in the latest updates. The absence of new adverse operating news may limit additional selling pressure.
• Neutral Sentiment: Several law firms—including Hagens Berman, Rosen Law Firm, SBS Law, Pomerantz, Faruqi & Faruqi, and Bernstein Liebhard—are soliciting investors to seek lead-plaintiff status by October 13, 2026. These announcements largely repeat the same underlying lawsuit rather than representing separate cases. Hagens Berman investor notice
• Neutral Sentiment: A reported September short-interest update showed zero shares sold short, but the figures appear incomplete or unreliable because the reported change was listed as “NaN.” It therefore provides little useful insight into trading direction.
• Negative Sentiment: The securities class action covers investors who bought Aardvark shares in or traceable to the February 2025 IPO, or who purchased securities between February 13, 2025, and May 14, 2026. The litigation alleges violations of federal securities laws by the company and certain officers and directors. Pomerantz class-action announcement
• Negative Sentiment: One investor notice alleges that IPO materials described Aardvark’s ARD-101 drug candidate as 99% restricted to the gut and reported no serious adverse events, while allegedly omitting safety risks that later led to an FDA clinical hold. These remain allegations, but the claims create potential legal costs, uncertainty, and reputational damage. AARD shareholder alert

Institutional Trading of Aardvark Therapeutics

A number of institutional investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Aardvark Therapeutics during the second quarter worth $42,000. Persistent Asset Partners Ltd acquired a new stake in Aardvark Therapeutics in the fourth quarter valued at $56,000. New York State Common Retirement Fund purchased a new stake in shares of Aardvark Therapeutics during the 2nd quarter worth $99,000. MetLife Investment Management LLC purchased a new stake in shares of Aardvark Therapeutics during the 4th quarter worth $102,000. Finally, Bank of America Corp DE grew its stake in shares of Aardvark Therapeutics by 72.9% during the 2nd quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock worth $108,000 after purchasing an additional 3,369 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Morgan Stanley reaffirmed an “underweight” rating and issued a $3.00 target price (down from $7.00) on shares of Aardvark Therapeutics in a report on Friday, May 15th. BTIG Research downgraded Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. HC Wainwright reissued a “neutral” rating and issued a $6.00 price objective on shares of Aardvark Therapeutics in a research note on Monday, July 20th. Wall Street Zen upgraded shares of Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, B. Riley Financial lowered their target price on shares of Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Aardvark Therapeutics currently has an average rating of “Hold” and an average price target of $15.33.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (ROR?). ROR? plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective ROR? inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.